BioMarin Pharmaceutical Newswire

BioMarin Pharmaceutical Newswire

Comprehensive Real-Time News Feed for BioMarin Pharmaceutical.

Results 1 - 20 of 896 in BioMarin Pharmaceutical

  1. BioMarin Pharmaceutical Inc. (BMRN) PT Set at $115.00 by SunTrust Banks, Inc.Read the original story

    37 min ago | AmericanBankingNews.com

    ... Several other brokerages also recently commented on BMRN. Sanford C. Bernstein started coverage on BioMarin Pharmaceutical in a report on Thursday, July 27th. They set a "market perform" rating and a $89.00 price target on the stock. Evercore ISI ...

    Comment?

  2. BioMarin Pharmaceutical Inc. (BMRN) Stock Price Down 0.1%Read the original story

    10 hrs ago | Daily Political

    BioMarin Pharmaceutical Inc. shares fell 0.1% during trading on Thursday . The stock traded as low as $86.90 and last traded at $88.70.

    Comment?

  3. BioMarin Pharmaceutical Inc. (BMRN) Receives "Buy" Rating from BMO Capital MarketsRead the original story

    Yesterday | AmericanBankingNews.com

    ... an "overweight" rating and issued a $117.00 price target (up previously from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Goldman Sachs Group, Inc. (The) reaffirmed a "buy" rating and issued a $129.00 ...

    Comment?

  4. BioMarin Pharmaceutical Inc. (BMRN) Downgraded to "Sell" at Zacks Investment ResearchRead the original story

    Yesterday | IntersportsWire

    ... Other analysts also recently issued research reports about the company. BidaskClub downgraded BioMarin Pharmaceutical from a hold rating to a sell rating in a research report on Monday, July 24th. Stifel Nicolaus reaffirmed a buy rating and issued a ...

    Comment?

  5. BioMarin Pharmaceutical Inc. (BMRN) PT Set at $115.00 by SunTrust Banks, Inc.Read the original story

    Yesterday | IntersportsWire

    ... "overweight" rating and issued a $117.00 price objective (up previously from $115.00) on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Goldman Sachs Group, Inc. (The) reiterated a "buy" rating and set a $129.00 price target ...

    Comment?

  6. BioMarin Pharmaceutical (BMRN) and Alexion Pharmaceuticals (ALXN) Head to Head ReviewRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    BioMarin Pharmaceutical and Alexion Pharmaceuticals are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. 97.3% of BioMarin Pharmaceutical shares are held by institutional investors.

    Comment?

  7. Deane Retirement Strategies, Inc. Buys iShares Core U.S. ...Read the original story w/Photo

    Thursday | GuruFocus.com

    ... an estimated average price of $476.48. Deane Retirement Strategies, Inc. sold out the holdings in Biomarin Pharmaceutical Inc. The sale prices were between $80.6 and $94.95, with an estimated average price of $88.32. Deane Retirement Strategies, ...

    Comment?

  8. BioMarin Pharmaceutical Inc. (BMRN) Price Target Raised to $124.00 at Credit Suisse GroupRead the original story

    Thursday | AmericanBankingNews.com

    ... have also issued research reports about the stock. Zacks Investment Research lowered shares of BioMarin Pharmaceutical from a "hold" rating to a "sell" rating in a research report on Monday. Goldman Sachs Group, Inc. (The) reaffirmed a "buy" rating ...

    Comment?

  9. On a Roll: BioMarin Reports IND and Clinical Trial DevelopmentsRead the original story w/Photo

    Wednesday Oct 18 | BioSpace

    BioMarin Pharmaceutical Inc. updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. "We are pleased to share the progress of our development programs in therapies to treat rare genetic diseases; hemophilia A, PKU, achondroplasia and our next IND into Friedreich's Ataxia," said Hank Fuchs, M.D., President Worldwide Research and Development of BioMarin.

    Comment?

  10. BioMarin Pharmaceutical Inc. (BMRN) Rating Reiterated by Leerink SwannRead the original story

    Thursday | AmericanBankingNews.com

    ... other research firms have also recently weighed in on BMRN. Zacks Investment Research cut shares of BioMarin Pharmaceutical from a "hold" rating to a "sell" rating in a research report on Monday. Goldman Sachs Group, Inc. (The) restated a "buy" ...

    Comment?

  11. BioMarin Pharmaceutical Inc. (BMRN) to Release Earnings on ThursdayRead the original story

    Wednesday | AmericanBankingNews.com

    BioMarin Pharmaceutical Inc. is scheduled to be posting its quarterly earnings results after the market closes on Thursday, October 26th. Analysts expect BioMarin Pharmaceutical to post earnings of per share for the quarter.

    Comment?

  12. BioMarin Pharmaceutical: Cramer's Top TakeawaysRead the original story w/Photo

    Wednesday | TheStreet.com

    In an "Executive Decision" segment, Cramer sat down with JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical , shares of which declined today by 5.6% after the company's analyst day. Bienaime said they offered an exciting update on their drug portfolio, which now includes six drugs on the market and another three in development.

    Comment?

  13. BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New YorkRead the original story

    Wednesday Oct 18 | PressReleasePoint

    / / -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. "We are pleased to share the progress of our ...

    Comment?

  14. Zacks Investment Research Downgrades BioMarin Pharmaceutical Inc. (BMRN) to SellRead the original story

    Wednesday Oct 18 | Daily Political

    ... commented on BMRN. Wedbush reaffirmed a "neutral" rating and set a $108.00 target price on shares of BioMarin Pharmaceutical in a research note on Monday, August 7th. Jefferies Group LLC reaffirmed a "buy" rating and set a $116.00 target price on ...

    Comment?

  15. Recent Analysts' Ratings Changes for BioMarin PharmaceuticalRead the original story

    Tuesday Oct 17 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of BioMarin Pharmaceutical in the last few weeks: 10/16/2017 - BioMarin Pharmaceutical was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. According to Zacks, "BioMarin should continue to see growth in both its orphan disease drugs Vimizim and Kuvan in 2017 backed by robust patient growth and penetration.

    Comment?

  16. Head to Head Comparison: BioMarin Pharmaceutical (BMRN) & Its RivalsRead the original story

    Monday Oct 16 | IntersportsWire

    BioMarin Pharmaceutical is one of 45 publicly-traded companies in the "Biopharmaceuticals" industry, but how does it compare to its competitors? We will compare BioMarin Pharmaceutical to similar businesses based on the strength of its profitability, earnings, dividends, institutional ownership, valuation, analyst recommendations and risk. 97.3% of BioMarin Pharmaceutical shares are owned by institutional investors.

    Comment?

  17. Comparing BioMarin Pharmaceutical (BMRN) & Its CompetitorsRead the original story

    Monday Oct 16 | AmericanBankingNews.com

    BioMarin Pharmaceutical is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it contrast to its rivals? We will compare BioMarin Pharmaceutical to similar businesses based on the strength of its analyst recommendations, valuation, dividends, institutional ownership, risk, earnings and profitability. BioMarin Pharmaceutical currently has a consensus price target of $111.25, suggesting a potential upside of 17.53%.

    Comment?

  18. BioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing BellRead the original story w/Photo

    Monday Oct 16 | GlobeNewswire

    What: BioMarin Pharmaceutical, Inc. , a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes, will visit the Nasdaq MarketSite in Times Square in celebration of the company's 20th anniversary. Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/NASDAQ .

    Comment?

  19. BioMarin Pharmaceutical Inc. (BMRN) Receives $106.45 Average PT from BrokeragesRead the original story

    Sunday Oct 15 | The Breeze

    Shares of BioMarin Pharmaceutical Inc. have been assigned a consensus recommendation of "Buy" from the twenty-seven brokerages that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, nine have given a hold rating and sixteen have assigned a buy rating to the company.

    Comment?

  20. Contrasting Alimera SciencesRead the original story w/Photo

    Saturday Oct 14 | Daily Political

    Alimera Sciences and BioMarin Pharmaceutical are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Alimera Sciences has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.

    Comment?